Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Maciá MD[au]:

Antibiotic treatment of biofilm infections. Ciofu O et al. APMIS. (2017)

Antimicrobial susceptibility testing in biofilm-growing bacteria. Macià MD et al. Clin Microbiol Infect. (2014)

Microbiological diagnosis of biofilm-related infections. Macià MD et al. Enferm Infecc Microbiol Clin. (2018)

Search results

Items: 30

1.

Treatment outcome in dually HIV-1 and HIV-2 coinfected patients living in Spain.

Requena S, Caballero E, Lozano AB, Ríos-Villegas MJ, Benito R, Rojo S, Cabezas T, Macià MD, Nieto MDC, Soriano V, de Mendoza C; Spanish HIV-2 Study Group.

AIDS. 2019 Nov 15;33(14):2167-2172. doi: 10.1097/QAD.0000000000002338.

PMID:
31373918
2.

Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype.

von Massow G, Garcia-Cehic D, Gregori J, Rodriguez-Frias F, Macià MD, Escarda A, Esteban JI, Quer J.

Infect Drug Resist. 2019 Apr 24;12:947-955. doi: 10.2147/IDR.S195441. eCollection 2019.

3.

Social Behavior of Antibiotic Resistant Mutants Within Pseudomonas aeruginosa Biofilm Communities.

Rojo-Molinero E, Macià MD, Oliver A.

Front Microbiol. 2019 Mar 22;10:570. doi: 10.3389/fmicb.2019.00570. eCollection 2019.

4.

Microbiological diagnosis of biofilm-related infections.

Macià MD, Del Pozo JL, Díez-Aguilar M, Guinea J.

Enferm Infecc Microbiol Clin. 2018 Jun - Jul;36(6):375-381. doi: 10.1016/j.eimc.2017.04.006. Epub 2017 May 27. Review. English, Spanish.

PMID:
28558916
5.

Antibiotic treatment of biofilm infections.

Ciofu O, Rojo-Molinero E, Macià MD, Oliver A.

APMIS. 2017 Apr;125(4):304-319. doi: 10.1111/apm.12673. Review.

PMID:
28407419
6.

Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.

Rojo-Molinero E, Macià MD, Rubio R, Moyà B, Cabot G, López-Causapé C, Pérez JL, Cantón R, Oliver A.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2912-22. doi: 10.1128/AAC.00196-16. Print 2016 May.

7.

The problems of antibiotic resistance in cystic fibrosis and solutions.

López-Causapé C, Rojo-Molinero E, Macià MD, Oliver A.

Expert Rev Respir Med. 2015 Feb;9(1):73-88. doi: 10.1586/17476348.2015.995640. Epub 2014 Dec 26. Review.

PMID:
25541089
8.

Antimicrobial susceptibility testing in biofilm-growing bacteria.

Macià MD, Rojo-Molinero E, Oliver A.

Clin Microbiol Infect. 2014 Oct;20(10):981-90. doi: 10.1111/1469-0691.12651. Epub 2014 Jun 14. Review.

9.

First report of an OXA-23 carbapenemase-producing Acinetobacter baumannii clinical isolate related to Tn2006 in Spain.

Espinal P, Macià MD, Roca I, Gato E, Ruíz E, Fernández-Cuenca F, Oliver A, Rodríguez-Baño J, Bou G, Tomás M, Vila J.

Antimicrob Agents Chemother. 2013 Jan;57(1):589-91. doi: 10.1128/AAC.01157-12. Epub 2012 Oct 15.

10.

Alterations of OprD in carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study.

Ocampo-Sosa AA, Cabot G, Rodríguez C, Roman E, Tubau F, Macia MD, Moya B, Zamorano L, Suárez C, Peña C, Domínguez MA, Moncalián G, Oliver A, Martínez-Martínez L; Spanish Network for Research in Infectious Diseases (REIPI).

Antimicrob Agents Chemother. 2012 Apr;56(4):1703-13. doi: 10.1128/AAC.05451-11. Epub 2012 Jan 30.

11.

Evolution and adaptation in Pseudomonas aeruginosa biofilms driven by mismatch repair system-deficient mutators.

Luján AM, Maciá MD, Yang L, Molin S, Oliver A, Smania AM.

PLoS One. 2011;6(11):e27842. doi: 10.1371/journal.pone.0027842. Epub 2011 Nov 17.

12.

Development of antibiotic resistance and up-regulation of the antimutator gene pfpI in mutator Pseudomonas aeruginosa due to inactivation of two DNA oxidative repair genes (mutY, mutM).

Mandsberg LF, Maciá MD, Bergmann KR, Christiansen LE, Alhede M, Kirkby N, Høiby N, Oliver A, Ciofu O.

FEMS Microbiol Lett. 2011 Nov;324(1):28-37. doi: 10.1111/j.1574-6968.2011.02383.x. Epub 2011 Sep 13.

13.

Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment.

Macià MD, Pérez JL, Molin S, Oliver A.

Antimicrob Agents Chemother. 2011 Nov;55(11):5230-7. doi: 10.1128/AAC.00617-11. Epub 2011 Aug 22.

14.

Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth.

Mulet X, Moyá B, Juan C, Macià MD, Pérez JL, Blázquez J, Oliver A.

Antimicrob Agents Chemother. 2011 Oct;55(10):4560-8. doi: 10.1128/AAC.00519-11. Epub 2011 Aug 1.

15.

Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.

Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A; Spanish Network for Research in Infectious Diseases (REIPI).

Antimicrob Agents Chemother. 2011 May;55(5):1906-11. doi: 10.1128/AAC.01645-10. Epub 2011 Feb 28.

16.

Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease.

Valderrey AD, Pozuelo MJ, Jiménez PA, Maciá MD, Oliver A, Rotger R.

Diagn Microbiol Infect Dis. 2010 Sep;68(1):20-7. doi: 10.1016/j.diagmicrobio.2010.04.008.

PMID:
20727465
17.

Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1.

Riera E, Macià MD, Mena A, Mulet X, Pérez JL, Ge Y, Oliver A.

J Antimicrob Chemother. 2010 Jul;65(7):1399-404. doi: 10.1093/jac/dkq143. Epub 2010 Apr 30.

PMID:
20435779
18.

Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.

Rodríguez-Rojas A, Maciá MD, Couce A, Gómez C, Castañeda-García A, Oliver A, Blázquez J.

PLoS One. 2010 Apr 15;5(4):e10193. doi: 10.1371/journal.pone.0010193.

19.

Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.

Mulet X, Maciá MD, Mena A, Juan C, Pérez JL, Oliver A.

Antimicrob Agents Chemother. 2009 Apr;53(4):1552-60. doi: 10.1128/AAC.01264-08. Epub 2009 Feb 2.

20.

Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease.

Martínez-Solano L, Macia MD, Fajardo A, Oliver A, Martinez JL.

Clin Infect Dis. 2008 Dec 15;47(12):1526-33. doi: 10.1086/593186.

PMID:
18990062
21.

Coevolution with viruses drives the evolution of bacterial mutation rates.

Pal C, Maciá MD, Oliver A, Schachar I, Buckling A.

Nature. 2007 Dec 13;450(7172):1079-81. Epub 2007 Dec 2.

PMID:
18059461
22.

Pseudomonas aeruginosa RsmA plays an important role during murine infection by influencing colonization, virulence, persistence, and pulmonary inflammation.

Mulcahy H, O'Callaghan J, O'Grady EP, Maciá MD, Borrell N, Gómez C, Casey PG, Hill C, Adams C, Gahan CG, Oliver A, O'Gara F.

Infect Immun. 2008 Feb;76(2):632-8. Epub 2007 Nov 19.

23.

Increased susceptibility to colistin in hypermutable Pseudomonas aeruginosa strains from chronic respiratory infections.

Maciá MD, Mena A, Borrell N, Pérez JL, Oliver A.

Antimicrob Agents Chemother. 2007 Dec;51(12):4531-2. Epub 2007 Sep 24. No abstract available.

24.

Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.

Plasencia V, Borrell N, Maciá MD, Moya B, Pérez JL, Oliver A.

Antimicrob Agents Chemother. 2007 Jul;51(7):2574-81. Epub 2007 Apr 30.

25.

Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice.

Mena A, Maciá MD, Borrell N, Moya B, de Francisco T, Pérez JL, Oliver A.

J Bacteriol. 2007 May;189(9):3665-8. Epub 2007 Feb 16.

26.

Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.

Maciá MD, Borrell N, Segura M, Gómez C, Pérez JL, Oliver A.

Antimicrob Agents Chemother. 2006 Mar;50(3):975-83.

27.

Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains.

Juan C, Maciá MD, Gutiérrez O, Vidal C, Pérez JL, Oliver A.

Antimicrob Agents Chemother. 2005 Nov;49(11):4733-8.

28.

[Molecular characterization of a glycopeptide-resistant Enterococcus faecalis outbreak in an intensive care unit].

Maciá MD, Juan C, Oliver A, Hidalgo O, Pérez JL.

Enferm Infecc Microbiol Clin. 2005 Oct;23(8):460-3. Spanish.

PMID:
16185558
29.

Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections.

Maciá MD, Blanquer D, Togores B, Sauleda J, Pérez JL, Oliver A.

Antimicrob Agents Chemother. 2005 Aug;49(8):3382-6.

30.

Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion.

Maciá MD, Borrell N, Pérez JL, Oliver A.

Antimicrob Agents Chemother. 2004 Jul;48(7):2665-72.

Supplemental Content

Loading ...
Support Center